Mesoblast, a leading global stem cell therapy development company, has taken out exclusive rights to patents covering dental pulp stem cells (DPSC), with the hope of treating conditions such as Parkinson's disease and stroke.
In their presentation to the Jeffries Annual Global Healthcare Conference in June, 1 Mesoblast suggested DPSC will play a vital role in their new corporate strategy for product development to treat neurologic conditions. Recent studies have shown that due to their neural crest origin, DPSC have unique properties, which make them more effective in the protection and repair of neural cells and tissues than other adult stem cells. Research by Karaöz et al. 2 emphasises the special characteristics of DPSC, with an in vitro study demonstrating how the pulp stem cells were able to differentiate into neural cells as well as vascular epithelial cells. The conclusions of the study are promising for the development of clinical uses of DPSC for neurodegenerative diseases.
DPSC are STRO-1 (a stem cell marker) positive, making them highly suitable for regenerative treatments. As producers of high levels of neurotrophic factors, Mesoblast is focusing on using their potential in the treatment of Huntington's and Parkinson's, affecting almost 135,000 in the UK; stroke, affecting around 150,000 each year in the UK; and acute spinal cord injury, paralysing approximately 1,200 each year in the UK. Inspired by their encounters and the revelation that Philips was an avid BDJ reader, the Army pair returned to the UK where Major Konarzewski won a bronze medal in the javelin at the Army Champs and Capt Smith went on to win his fifth Inter-Services 400 m hurdle title competing against the RAF and Navy. Capt Smith has also been selected to be a part of the London 2012 Medical Team in his spare time, providing dental cover at various venues in the Olympic Village. 
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